SMS Pharmaceuticals in FY26: Profit growth, ibuprofen scale-up, and a cautious FY27 outlook

SMS Pharmaceuticals ended FY26 with steady top-line growth and a much stronger jump in profitability. Consolidated revenue from operations rose to ₹887 crore, up 13% year on year. EBITDA increased to ₹171 crore, up 23%, and the EBITDA margin improved to 19% in the investor presentation, with management describing FY26 margins at 20% on the earnings call. Profit after tax (including share of profit from associate company VKT Pharma) reached ₹102 crore, up 47%.

The March quarter showed a slightly different mix of signals. Q4 revenue was ₹238 crore, and EBITDA was ₹40 crore with a 17% margin. PAT rose to ₹33 crore, helped by an approximately ₹12 crore share of profit from VKT Pharma. Management clarified that excluding this associate contribution, PAT for the quarter was about ₹21 crore, broadly in line with the previous year’s quarter.

What drove FY26: mix, backward integration, and associate contribution

In both the investor deck and the concall, the company repeatedly linked its improved profitability to backward integration and product mix. FY26 EBITDA growth outpaced revenue growth, which is consistent with this explanation.

A major contributor to scale is the company’s anti-inflammatory portfolio, where ibuprofen plays an outsized role. In the concall Q&A, management stated ibuprofen contributes roughly 20% of total revenue. At the same time, the therapeutic mix shows that anti-inflammatory APIs accounted for 20% of FY26 revenue, while ARVs were the largest at 28%. Anti-diabetic contributed 15%, anti-migraine 11%, and the rest came from anti-erectile dysfunction, anti-epileptic, anti-anginal, anti-ulcer, and other products.

The associate company VKT Pharma was another visible tailwind. In the consolidated P&L table, share of associate profit increased to ₹13.99 crore in FY26 versus ₹1.74 crore in FY25. Management said it expects VKT Pharma’s full-year contribution to be sustainable and strengthen into FY27.

FY26 snapshot (consolidated)

Portfolio and market presence: export-heavy and regulated-market focused

SMS Pharmaceuticals positions itself as a diversified API manufacturer with a heavy tilt to regulated markets. The investor presentation states that 88% of revenue comes from regulatory markets. In FY26, revenue by location was disclosed as North America 31%, Asia excluding India 26%, Europe 22%, EOU/SEZ/DE sales 15%, and India 6%.

Customer mix is also disclosed, but it carries an important nuance. Large pharma contributed 59% of FY26 revenue and mid-to-small pharma 41%. The largest customer alone contributed 28% of revenue, with the next 2 to 10 customers at 31%, and the remaining base at 41%. In the concall, management acknowledged the concentration question but stated that the large customer contribution comes from multiple products, not a single product.

The next leg: capex, capacity utilisation, and filings momentum

The strategic roadmap in the presentation is anchored around capacity expansion, higher utilisation, backward integration, and new product filings.

The company’s current capex program is stated at ₹280 crore, targeted for completion by FY27. The deck indicates capex is oriented toward expanding existing APIs, building capacities for new APIs in the pipeline, and land acquisition for a greenfield project. Management added in the concall that around ₹130 crore has already been invested.

A key piece of this capex is ibuprofen capacity. Management stated it is increasing capacity from 500 tons per month to 800 metric tons per month, citing about 80% utilisation at the current level. The commissioning timeline was described as completion by March FY27, with incremental revenues expected from FY28.

Beyond physical capacity, the company highlighted regulatory and pipeline work. The presentation notes 120+ DMFs filed till date and 20 new products added since FY22. On the concall, management gave a clearer near-term run rate: 12 DMFs and CEPS were filed in FY26, with 10 filings targeted in FY27 and another 10 planned for FY28. The presentation also states that R&D investment is targeted to double over the next 15 months.

The company also spoke about two newer vectors, though they remain early-stage.

First, peptides. Management said it has invested in peptide R&D capabilities, initial results are promising, and it is working on multiple products. It expects to provide more clarity on the commercial roadmap after the next two quarters and sees meaningful contributions from FY29 onwards.

Second, CDMO. Management described CDMO as an area of strategic focus and said it is progressing, with a fuller update expected after the next two quarters.

FY27 guidance: conservative on growth, confident on margins

Management’s FY27 stance was deliberately cautious on the top line and more confident on profitability.

The explicit guidance provided was 15% revenue growth in FY27, factoring in uncertainties from geopolitical developments in the Middle East that can disrupt logistics and supply chain stability. Management also stated it aims to improve upon FY26 EBITDA margins.

In the Q&A, management went further on margin aspiration. It stated the company’s historical highest EBITDA margin was around 22%, and it is targeting that level in FY27, with an intent to exceed it in subsequent years.

The quarter’s gross margin movement offers context for this caution. When asked about a quarter-on-quarter decline in gross margin, management attributed it to increased raw material consumption driven by higher solvent costs in March, which it linked to war-related disruptions.

Takeaways

FY26 reinforced that SMS Pharmaceuticals’ current playbook is designed to turn scale and integration into better earnings quality. The year delivered 13% revenue growth, but a faster rise in EBITDA and PAT, aided by backward integration, mix improvement, and a sharp increase in the share of associate profit from VKT Pharma.

The near-term investment case now hinges on execution of the ₹280 crore capex program, particularly the ibuprofen capacity expansion, and whether utilisation and margins track management’s stated ambition. FY27 guidance of 15% growth reflects external uncertainty, but the company’s focus on improving EBITDA margins suggests management believes operational levers can offset volatility in logistics and inputs. The larger inflection from capacity and new products is positioned for FY28 and beyond.